Safety of SGI-1776, A PIM Kinase Inhibitor in Refractory Prostate Cancer and Relapsed/Refractory Non Hodgkin's Lymphoma
Clinical trial NCT00848601 · TERMINATED
Trial details
- NCT number
- NCT00848601
- Sponsor
- Astex Pharmaceuticals, Inc.
- Status
- TERMINATED
- Phase
- Phase 1
- Study type
- INTERVENTIONAL
- Start date
- 2009-02-01
- Primary completion
- 2010-10-01
- Enrollment
- 14
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.